pharmaphorum

AUGUST 16, 2022

Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 Now, Merck has made its own play, partnering with Orna on its proprietary ‘oRNA’ technology, which stands for circular RNA. billion, including $150 million upfront.

RNA 98

RNA Vaccination Vaccine Clinical Trials 98

Bio Pharma Dive

FEBRUARY 10, 2023

The pharma and partner BioNTech have kicked off the first human trial of a messenger RNA shot for shingles, believing there’s room to clear the high bar set by GSK’s rival vaccine.

Vaccination 358

Vaccination Vaccine RNA Trials 358

XTalks

SEPTEMBER 13, 2021

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 105

RNA Genetics Genetic Disease Medicine 105

pharmaphorum

MARCH 3, 2024

Avidity Biosciences files $400m private placement as it prepares for phase 3 trial of lead antibody oligonucleotide conjugate AOC 1001 in rare disease DM1

RNA 105

RNA Antibody Trials 105

Bio Pharma Dive

MAY 19, 2023

The biotech, best known for its vaccine research, said its clinical trial is the first to report results of a messenger RNA therapeutic designed for intracellular protein replacement.

RNA 284

RNA Medicine Clinical Trials Clinical Trials 284

Roots Analysis

NOVEMBER 6, 2023

RNA-based therapeutics have completely revolutionized the healthcare segment, greatly influencing the study and treatment of human diseases by conferring precise targeting ability to therapeutic modalities. The below figure presents the distribution of next generation RNA-based therapeutics and RNA-based vaccines, based on type of molecule.

RNA 40

RNA Vaccination Vaccine Clinical Trials 40

Drug Discovery World

APRIL 11, 2023

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. The technology can also generate synthetic data sets, or make human trials more efficient, by identifying the most suitable patients, predicting outcomes and optimising dosages and regimens of drugs.

RNA 52

RNA Medicine Engineer Drugs 52

Drug Discovery World

DECEMBER 13, 2022

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. . Using RNA interference, researchers restored the normal biological function of FKTN in patient-derived cells, offering hope for a new therapy. . Modifying RNA function.

RNA 52

RNA Genetics Gene In-Vitro 52

Drug Discovery World

AUGUST 1, 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. However, these have not been as successful in clinical trials as hoped.

RNA 52

RNA Bioassay Genome Genomics 52

STAT News

JANUARY 9, 2023

An experimental RNA treatment reduced liver scarring in half of patients with an inherited disease called alpha-1 antitrypsin deficiency, or AATD, according to results from a mid-stage clinical trial reported Monday by its maker Arrowhead Pharmaceuticals.

RNA 98

RNA Clinical Trials Clinical Trials Trials 98

XTalks

MARCH 21, 2022

Credited as a pioneering RNA interference (RNAi) therapeutics company, Alnylam Pharmaceuticals is taking Pfizer and Moderna to court, claiming that the companies’ use of the lipid nanoparticle (LNP)-based RNA delivery technology in their mRNA COVID-19 vaccines infringes on a patented technology.

RNA 98

RNA Vaccination Vaccine Sales 98

Drug Discovery World

DECEMBER 5, 2022

Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies), lack of an optimal biomarker is one of the main challenges to clinical trial success. What you will learn: Overview: Relevance of single-cell RNA sequencing in your drug discovery toolkit.

RNA 52

RNA Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

DECEMBER 16, 2022

The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. . The post Biotech company raises $30M to target RNA modifying enzymes appeared first on Drug Discovery World (DDW).

RNA 52

RNA Immune Response Bioavailability Development 52

Fierce Pharma

APRIL 22, 2024

As a closely watched readout from Alnylam Pharmaceuticals' Amvuttra in the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) is expected in a few weeks, experts suggested the RNA si | As an all-important readout from Alnylam’s Amvuttra in the rare heart disease ATTR-CM is expected in a few weeks, experts suggested that the RNA (..)

RNA 97

RNA Trials 97

Fierce Pharma

FEBRUARY 15, 2024

Changing a clinical trial’s statistical analysis plan on the cusp of a readout? Changing a clinical trial’s statistical analysis plan on the cusp of a readout? That’s exactly what Alnylam just did for a closely watched study of its next-generation RNA interference therapy Amvuttra in a rare heart disease.

RNA 106

RNA Trials 106

XTalks

JANUARY 8, 2024

Whether it’s for a treatment for a chronic ambulatory condition, precision medicine or cell and gene therapy, there is a massive uptick in clinical trial complexity. It’s important to make sure that with this increase in clinical trial complexity, we don’t make our trials overly burdensome to sites or patients,” says Markham.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Gene Therapy 105

BioTech 365

JANUARY 17, 2022

Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 trial of HDT Bio’s RNA COVID-19 Vaccine Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 trial of HDT Bio’s RNA COVID-19 Vaccine HDT Bio’s RNA-based vaccine offers simpler … Continue reading →

RNA 52

RNA Vaccination Vaccine Trials 52

BioTech 365

AUGUST 31, 2021

HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India Vaccine Would Be India’s First Indigenous RNA Vaccine, Exemplifying HDT … Continue reading →

RNA 52

RNA Vaccination Vaccine Trials 52

pharmaphorum

JANUARY 6, 2022

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . The post Roivant joins RNA splicing push with Eisai deal appeared first on.

RNA 52

RNA Licensing Licensing Development 52

Pharmaceutical Technology

MARCH 28, 2023

There is much interest in the industry around RNA-based therapeutics as their utilisation in indications beyond Covid-19 come into focus. In December 2022, BioNTech initiated a Phase I clinical trial of BNT163 – an HSV vaccine candidate. In 2022, the company also started five first-in-human clinical trials from its oncology programme.

Vaccination 276

Vaccination Vaccine Development Clinical Trials 276

Drug Discovery World

DECEMBER 1, 2022

Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies), lack of an optimal biomarker is one of the main challenges to clinical trial success. What you will learn: Overview: Relevance of single-cell RNA sequencing in your drug discovery toolkit.

RNA 52

RNA Drugs Clinical Trials Clinical Trials 52

pharmaphorum

JULY 20, 2022

Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to fine-tune the expression of genes. ” The post CAMP4 raises $100m to take lead RNA drugs into clinic appeared first on.

RNA 52

RNA Genetic Disease Drugs Protein 52

BioTech 365

JULY 6, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Lilly invests in MiNA to fund trials of protein-upregulating RNA.Lilly invests in MiNA to fund trials of protein-upregulating RNA ntaylor Tue, 07/06/2021 – 07:58 from FierceBiotech: Biotech … Continue reading → (..)

RNA 40

RNA Protein Trials Research 40

BioTech 365

DECEMBER 13, 2021

HDT Bio Partner Quratis Doses First Healthy Volunteers in Phase 1 Trial of HDT Bio’s RNA COVID-19 Vaccine in South Korea HDT Bio Partner Quratis Doses First Healthy Volunteers in Phase 1 Trial of HDT Bio’s RNA COVID-19 Vaccine in … Continue reading →

RNA 52

RNA Vaccination Vaccine Trials 52

Bio Pharma Dive

AUGUST 11, 2022

The company will wind down five trials involving two drug candidates and lay off more staff, prioritizing instead its RNA-editing technology.

RNA 154

RNA Drugs Trials 154

STAT News

JANUARY 30, 2023

It is now possible to treat diseases with gene therapy, antisense oligonucleotides, messenger RNA (mRNA), noncoding RNA (known as small interfering RNA, or siRNA), and other gene-based modalities. New ways of conducting clinical trials have also emerged. The human genome was sequenced in 2003. Read the rest…

RNA 111

RNA Gene Therapy Drugs Gene 111

pharmaphorum

DECEMBER 14, 2022

The two partners have revealed the first clinical data from a phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – that are thought to be driving a patient’s cancer. Access to sequencing could, however, be a major obstacle at the population level.

Vaccination 98

Vaccination Vaccine Trials Gene Sequencing 98

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 16, 2022

The husband-and-wife team who co-founded BioNTech, the biotechnology company that partnered with Pfizer to develop an effective messenger-RNA (mRNA) shot against COVID-19, has predicted that a cancer vaccine could be widely available within the next decade.

Vaccination 179

Vaccination Vaccine RNA Development 179

Pharmaceutical Commerce

FEBRUARY 12, 2024

In clinical trials, bepirovirsen was found to recognize the RNA used by hepatitis B virus to replicate in infected liver cells.

RNA 52

RNA Clinical Trials Clinical Trials Trials 52

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. The trial will enrol up to 50 healthy volunteers aged 18 to 49.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Pharmaceutical Technology

JANUARY 19, 2023

“We look forward to working collaboratively with the FDA to bring the first RNA therapy directly targeting DUX4 to patients as quickly as possible.” AOC 1020 is currently being studied in the double-blind, randomised, placebo-controlled Phase I/II FORTITUDE clinical trial in nearly 70 FSHD adult patients.

Gene Expression 246

Gene Expression Gene Protein RNA 246

Pharmaceutical Technology

NOVEMBER 10, 2022

Olpasiran is entering a Phase III clinical trial to evaluate if the siRNA therapy can reduce cardiovascular event risk in atherosclerotic cardiovascular disease patients with increased Lp(a) levels. . The post Royalty Pharma acquires royalty interest in olpasiran for $250m appeared first on Pharmaceutical Technology.

RNA 130

RNA Sales Clinical Trials Clinical Trials 130

Pharmaceutical Technology

MAY 19, 2023

Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase I/II trials for T cell lymphoma. The financing will help to fast-track the development of other in vivo programming candidates into clinical trials.

In-Vivo 246

In-Vivo Gene Therapy Gene RNA 246

The Pharma Data

DECEMBER 10, 2020

Moderna has begun dosing adolescents in a phase 2/3 trial evaluating messenger RNA-based vaccine candidate mRNA-1273 and plans to enroll 3,000 U.S. participants aged 12 to 17. Source link.

Vaccination 52

Vaccination Vaccine Trials RNA 52

Pharmaceutical Technology

OCTOBER 14, 2022

In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs. It is currently being assessed in combination with Merck’s anti-PD-1 therapy, Keytruda, as an adjuvant treatment for high-risk melanoma patients in a Phase II clinical trial being conducted by Moderna.

Vaccination 289

Vaccination Vaccine Development Immune Response 289

Drug Discovery World

JULY 19, 2022

An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection. . The clinical trial has been launched by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate an investigational vaccine to prevent infection with Nipah virus.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Vaccination 52

Drug Discovery World

FEBRUARY 19, 2024

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).

Vaccination 52

Vaccination Vaccine Immune Response RNA 52